Medical Technologies
US Ban on SR-17018 Threatens the Future of Opioid Addiction Treatment Research
An emergency decision by the U.S. Drug Enforcement Administration (DEA) places the compound SR-17018 into Schedule I of controlled substances, raising concerns among scientists that promising medical research, which could provide a safe way to overcome opioid addiction, may be halted.
2026-11-04